John A. Johnson, MD, MBA: Type 2 diabetes has become an epidemic in the United States, and at WellCare, we consider it one of our top priorities because most of the members we serve have type 1 or type 2 diabetes. We rank that very high in our priority along with hypertension, hyperlipidemia, [and] heart and cardiovascular diseases such as heart failure, myocardial infarction, and stroke. Diabetes is a risk factor for all of the other types of cardiovascular diseases, [and therefore] all of our programs are designed to eradicate or treat diabetes as best as possible.
At WellCare, we have what’s called our case and disease management programs. These are programs that partner with the providers and patients (or members we serve) to help improve the outcomes of [a patient’s] disease. From a cost-avoidance perspective, we try to enhance the quality of services that our members receive by providing wraparound services or support. For example, with diabetes disease management, this involves a nurse or social worker identifying patient-centered barriers to care—whether access, transportation, or care gaps—and [working to figure out] how we can help that patient, or member of ours, get the services that they need and prioritize their care from their perspective.
At WellCare, this is a very big priority [and a reason why] all of our programs are interwoven. For example, we also have a program called Advocacy. Our Advocacy program identifies social-economic barriers that our diabetics may have in their communities—whether they live in a food desert where they don’t have access to healthy nutrition or they lack an ability to participate in an exercise program, carb counting, or meal planning. So, our Advocacy program identifies community partners that we can work with to enhance those services in a collaborative way.
Again, diabetes is at the core of what we do, and is the disease that we manage. Our belief is that if we can connect those patients (our members) to these services, then downstream, we can improve quality, improve clinical outcomes, and enhance the member experience.
Review: One-Shot Etranacogene Dezaparvovec Represents Game-Changing Gene Therapy for Hemophilia B
May 3rd 2024More than 20 years of gene therapy clinical research have led to etranacogene dezaparvovec’s use in hemophilia B, according to authors of a recent review—and it takes its place in a line of current and potentially many future genomic medicines for a range of diseases.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Shelly Lanning on How Employers Can Reduce Costs by Bridging Gaps in Women's Health Care
May 3rd 2024In a presentation at the Greater Philadelphia Business Coalition on Health Women’s Health Summit, Shelly Lanning, cofounder and president of Visana Health, addressed the need for comprehensive approaches in women’s health care and their coverage options.
Read More